Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study
This study was undertaken to assess humoral immune and cellular responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccination in CLL.
Methods: The presence of the spike antibodies was assessed at a median time of 14 days from the second vaccine dose of SARS-CoV2 in 70 CLL followed-up at a single institution.
Results: The antibody response rate (RR) in CLL patients was 58.5%, compared to 100%
of 57 healthy controls of the same sex and age (P
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | COVID-19 | Leukemia | SARS | Study | Vaccines